# OncoLUNG Dx - Order Form

## Biochemistry

<table>
<thead>
<tr>
<th>Tumor Markers</th>
<th>CA 15.3</th>
<th>CEA</th>
<th>CYFRA 21-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSE</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NSE</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

## Personal Data

### Gender
- [ ] Male  
- [ ] Female  
- [ ] Unknown

### Age (years):

- [ ]  

## Comorbidities

### Chronic Liver Disease:
- [ ] Yes  
- [ ] No  
- [ ] Unknown

### Pemphigus:
- [ ] Yes  
- [ ] No  
- [ ] Unknown

### Psoriasis:
- [ ] Yes  
- [ ] No  
- [ ] Unknown

### Renal Failure:
- [ ] Yes  
- [ ] No  
- [ ] Unknown

## CT Scan Image

### CT Findings:
- [ ] Nodules  
- [ ] Metastasis  
- [ ] No

### Nodule Size (mm):

- [ ]  

## Lifestyle

### Smoking:
- [ ] Never  
- [ ] Currently  
- [ ] Past  
- [ ] Unknown

## Order Information

- Ordered by:  
- Signature:  
- Order Date:  

## Disclaimer

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoLUNG Dx is a non-invasive blood test useful to suggest a possible diagnosis in patients with suspected malignancy in the lungs, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for patients with previous image findings suspicious of Lung Cancer that should be biopsied to verify malignancy, as well as smokers older than 55 years.

OncoLUNG Dx is based in a panel consisting of 6 serum Tumor Markers (CA 15.3, CEA, CYFRA 21-1, NSE, SCC and ProGRP), as well as clinical data to obtain the best performance (Sensitivity of 93.5% and Specificity of 96.2%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.